Our finding of similar incidence of non-fatal cardiovascular outcomes with GLP1-RA compared to DPP4i is in line with the recently published FLOW study that randomized people with early to mid-stage CKD to semaglutide or placebo, which reported similar incidence of non-fatal myocardial infarction and non-fatal stroke across the semaglutide and placebo treated groups, despite a significantly reduced risk of major kidney disease events and all-cause death 44
Complete ingredient breakdown Understanding what you are actually putting in your body matters more than any marketing claim
As we navigate the complexities of health and wellness, remember that every plasma donation counts
This gives you a baseline to work from
While they both have their pros and cons, they work well together synergistically
[DOI] [PubMed] [Google Scholar] 131.Ferrari D., Cysneiros R.M., Scorza C.A., Arida R.M., Cavalheiro E.A., de Almeida A.C., Scorza F.A